首页> 外文期刊>薬物動態 >Development of a sustained release preparation of diclofenac sodium and its pharmacokinetics in dogs
【24h】

Development of a sustained release preparation of diclofenac sodium and its pharmacokinetics in dogs

机译:在狗的双氯芬酸钠及其药代动力学的持续释放制备的发展

获取原文
获取原文并翻译 | 示例
           

摘要

Diclofenac sodium(DF-Na) is a phenylacetae non-steroidal anti-inflammatory agent,and has a good anti-inflammatory analgesic antipyretic effect.In this study,in consideration of daily variations in the severity of rheumatoid arthritis and osteoarthritis and to improve patient compliance,we developed sustained release preparations that are expected to be effective by a single daily administration.To select the most optimal prepaation for humans,a pharmacokinetic study was performed in dogs.We employed multiple units for control of the drug release rather than a single sustained release system in the designof a sustained relese preparation,and prepared four sustained release preparation,and prepared four sustained release preparations with different sustained release mechanisms. 1.A preparation coated with a combination of enteric polymer (PMA) and water-insoluble polymer(EC) to delay the solubilization and water permeation of the film compared to those in the PMA-coated control preparation. 2.A preparation in which the drug granules are coated with an enteric film(PMA) combined with an organic acid (fumaric acid) to delay the release of DF-Na. 3.A preparation containing sustained release granules coated with a combination of water-insoluble polymer(EC) and water-soluble polymer(PVP) to make the drug release time-dependent. 4.A preparation double-coated with a water-insoluble film (EC:PVP=2:1) and an enteric film (PMA) to delay the release of DF-Na.The four sustained release preparations with different mechanisms were selected based on the pharmacokinetic study in beagles for the next clinical study.
机译:双氯芬酸钠(DF-NA)是苯乙酰基非甾体抗炎剂,具有良好的抗炎镇痛的解热作用。本研究考虑到类风湿性关节炎和骨关节炎严重程度和改善患者的日常变化合规性,我们开发了持续的释放准备,预计每日每日施用都会有效。为人类选择最佳的最佳准备,在狗中进行药代动力学研究。我们采用多个单位来控制药物释放而不是单一的药物释放持续释放制剂设计中的持续释放系统,并制备了四种缓释制剂,并制备了具有不同持续释放机制的四种持续释放制剂。 1.通过肠溶聚合物(PMA)和水不溶性聚合物(EC)的组合涂覆的制剂,与PMA涂覆的对照制剂中的那些延迟膜的溶解和水渗透。 2.将药物颗粒涂覆有肠膜膜(PMA)的制剂与有机酸(富马酸)合并,以延迟DF-NA的释放。 3.将含有水不溶性聚合物(EC)和水溶性聚合物(PVP)的组合的含有缓释颗粒的制剂,以使药物释放时间依赖。 4.通过水不溶性薄膜(EC:PVP = 2:1)和肠膜膜(PMA)进行双涂覆的制剂,以延迟DF-NA的释放。基于以下选择具有不同机制的四个持续释放制剂术语中的下一个临床研究的药代动力学研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号